P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.
| Autor: | Silvennoinen, Raija, Partanen, Anu, Waage, Anders, Pečeliūnas, Valdas, Schjesvold, Fredrik, Anttila, Pekka, Uttervall, Katarina, Säily, Marjaana, Putkonen, Mervi, Carlson, Kristina, Haukas, Einar, Sankelo, Marja, Szatkowski, Damian, Hansson, Markus, Marttila, Anu, Axelsson, Per, Svensson, Ronald, Lauri, Birgitta, Mikkola, Maija, Karlsson, Conny |
|---|---|
| Zdroj: | HemaSphere; 2023 Supplement 3, Vol. 7, p1-2, 2p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|
Plný text